November 17, 2017 09:58 AM ESTUpdated 01:29 PM

Pfizer reshuffles top ranks with Albert Bourla as COO; Intra-cellular nabs Novartis vet Andrew Satlin as CMO

Amber Tong

→ Pfizer has promoted its Innovative Health chief Albert Bourla to the new role of chief operating officer, where he’s been given a special mandate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer reshuffles top ranks with Albert Bourla as COO; Intra-cellular nabs Novartis vet Andrew Satlin as CMO

Amber Tong

Sign up to read this article for free.

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Pfiz­er reshuf­fles top ranks with Al­bert Bourla as COO; In­tra-cel­lu­lar nabs No­var­tis vet An­drew Satlin as CMO

Amber Tong

Sign up to read this article for free.

more like this

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Pfizer reshuffles top ranks with Albert Bourla as COO; Intra-cellular nabs Novartis vet Andrew Satlin as CMO

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify